NCT06854159

Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2025-08-07Est. Completion: 2028-10

Enrollment target: 34 participants

Locations

University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

Hematologic Cancer

Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood …

Tempe, United StatesEst. completion Mar 2031

Diffuse Large B-Cell Lymphoma

The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer wit…

Gilbert, United StatesEst. completion Jul 2, 2029

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.